Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
326 Leser
Artikel bewerten:
(1)

Decisions of Sampo plc's Annual General Meeting

Finanznachrichten News

SAMPO PLC DECISIONS OF GENERAL MEETING 19 May 2021 at 2:15 pm


Decisions of Sampo plc's Annual General Meeting

The Annual General Meeting of Sampo plc, held today on 19 May 2021, decided to distribute a dividend of EUR 1.70 per share for 2020. The record date for dividend payment is 21 May 2021 and the dividend will be paid on 28 May 2021. The Annual General Meeting adopted the financial accounts for 2020 and discharged the Board of Directors and the CEO from liability for the financial year.

The Annual General Meeting elected eight members to the Board of Directors. The following members were re-elected to the Board: Christian Clausen, Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm, Johanna Lamminen, Risto Murto and Björn Wahlroos. Markus Rauramo was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting.

At its organizational meeting, the Board elected Björn Wahlroos as Chair and Jannica Fagerholm as Vice Chair. Christian Clausen, Risto Murto and Björn Wahlroos (Chair) were elected to the Nomination and Remuneration Committee as well as Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm (Chair), Johanna Lamminen and Markus Rauramo were elected to the Audit Committee.

All the Board members have been determined to be independent of the company and its major shareholders under the rules of the Finnish Corporate Governance Code 2020. The curriculum vitaes of the Board Members are available at www.sampo.com/board.

The Annual General Meeting decided to pay the following fees to the members of the Board of Directors until the close of the 2022 Annual General Meeting: the Chair of the Board will be paid an annual fee of EUR 184,000 and other members of the Board will be paid EUR 95,000 each. Furthermore, the members of the Board and its Committees will be paid the following annual fees: the Vice Chair of the Board EUR 26,000, the Chair of the Audit Committee EUR 26,000 and the member of the Audit Committee EUR 6,000. A Board member shall, in accordance with the resolution of the Annual General Meeting, acquire Sampo plc's A shares at the price paid in public trading for 50 per cent of his/her annual fee excluding taxes and similar payments.

The Annual General Meeting accepted Sampo plc's Remuneration Report for Governing Bodies. The resolution is advisory.

Deloitte Ltd was elected as Auditor. The Auditor will be paid a fee determined by an invoice approved by Sampo. Jukka Vattulainen, APA, will act as the principally responsible auditor.

The Annual General Meeting authorized the Board to repurchase a maximum of 50,000,000 Sampo A shares. The price paid for the shares repurchased under the authorization shall be based on the current market price of Sampo A shares on the securities market. The authorization will be valid until the close of the next Annual General Meeting, nevertheless not more than 18 months after AGM's decision.

There were altogether 330,774,332 shares (59.56 per cent of shares) and 335,574,332 votes (59.91 per cent of all votes) in the company represented, including advance voting and a proxy representation, at the Annual General Meeting. The voting results of the AGM are available on a table attached to this release.

The proposals approved by the Annual General Meeting as well as Sampo plc's Remuneration Report for Governing Bodies were published in stock exchange releases on 11 February and 17 March 2021. The documents are available in their entirety at Sampo's AGM website at www.sampo.com/agm.

The minutes of the Annual General Meeting will be available for viewing at the AGM website and at Sampo plc's head office at Fabianinkatu 27, Helsinki, Finland, by the end of 2 June 2021.


SAMPO PLC

Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030

Maria Silander
Communications Manager, Media Relations
tel. +358 10 516 0031

Mirko Hurmerinta
IR & Communications Specialist
tel. +358 10 516 0032

Distribution:
Nasdaq Helsinki
London Stock Exchange
The principal media
Financial Supervisory Authority
www.sampo.com

ANNEX

Voting results of the Annual General Meeting

Board proposals for the AGMForAgainstAbstained from voting
Adoption of the Financial Statements331,393,502
(98.87%)
3,775,321
(1.13%)
402,267
(0.12%)
Resolution on the use of the profit shown on the balance sheet and the payment of dividend334,685,313
(99.74%)
878,061
(0.26%)
10,958
(0.00%)
Resolution on the discharge of the members of the Board of Directors and the Group CEO and President from liability for the financial year 2020329,381,908
(99.92%)
273,367
(0.08%)
585,144
(0.18%)
Handling of the Remuneration Report for Governing Bodies217,928,781
(65.00%)
117,365,936
(35.00%)
272,589
(0.08%)
Resolution on the remuneration of the members of the Board of Directors335,009,963
(99.84%)
530,132
(0.16%)
29,821
(0.01%)
Resolution on the number of members of the Board of Directors335,540,174
(100.00%)
799
(0.00%)
28,721
(0.01%)
Election of the members of the Board of Directors304,764,402
(92.37%)
25,161,160
(7.63%)
5,644,425
(1.71%)
Resolution on the remuneration of the Auditor328,777,671
(97.98%)
6,767,601
(2.02%)
27,298
(0.01%)
Election of the Auditor330,655,851
(99.01%)
3,317,614
(0.99%)
1,593,932
(0.48%)
Authorizing the Board of Directors to decide on the repurchase of the company's own shares335,221,209
(99.95%)
174,965
(0.05%)
172,342
(0.05%)

© 2021 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.